Health care stocks were steady premarket Wednesday with the iShares Biotechnology ETF (IBB) and Health Care Select Sector SPDR Fund (XLV) recently inactive.
Alto Neuroscience (ANRO) shares tumbled by over 62% after the company said a phase 2b study of ALTO-100 in patients with major depressive disorder failed to meet its primary endpoint compared with placebo.
Evotec (EVO) shares were almost 8% higher after the company said it will receive a $50 million payment as part of its partnership with Bristol Myers Squibb (BMY) to develop a molecular glue-based pipeline.
Thermo Fisher Scientific (TMO) shares were down almost 2% after the company reported Q3 adjusted earnings of $5.28 per diluted share, down from $5.69 a year earlier.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。